Orlando, Florida — The 2026 annual meeting of the Radiosurgery Society (RSS), the world's premier gathering in the field of radiosurgery, recently concluded successfully. The conference brought together top experts, scholars, and industry leaders from around the globe to discuss cutting-edge advances in radiosurgery and precision radiotherapy.
A proud highlight for China: research powered by Raycision's domestically developed SHARP 1000 Multimodal Image-Guided Precision Radiotherapy System was selected for an oral presentation. Titled "SCART Regulates the Immune Microenvironment and Enhances Ablation Effects in a Mouse Liver Cancer Model: Insights from Histopathology and Spatial Transcriptomics", the study demonstrated the system's capabilities and earned high recognition from international peers, shining a spotlight on Chinese innovation in high-end medical equipment.
The RSS annual meeting is one of the most authoritative and influential academic platforms in the global radiosurgery community. It focuses on key areas such as stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT), serving as a vital venue for sharing the latest research and exploring future technological trends.
As the world's first multimodal (CT + optical molecular imaging) image-guided high-end radiotherapy system developed by Raycision, the SHARP 1000 has become the "gold standard" equipment for preclinical tumor radiotherapy research thanks to three core strengths.
1. Millimeter-Level Precision for True "Targeted Strikes" on Tumors
The system integrates an ultra-high-resolution Micro-CT imaging module (resolution ≤50μm) with 3D optical molecular imaging technology (resolution ≤200μm). This allows precise localization and three-dimensional reconstruction of tumors in small animals. By fusing multimodal images, it simultaneously captures both structural and functional information of tumors, effectively solving common industry challenges such as inaccurate target identification and positioning errors that plague traditional single-modality guidance.
2. AI-Powered Intelligence for Lightning-Fast Treatment Planning
Addressing the traditionally time-consuming and labor-intensive process of target contouring in preclinical studies, the SHARP 1000 features AI-driven intelligent auto-contouring algorithms that can automatically delineate mouse organ targets in just 5 seconds. Combined with GPU-accelerated Monte Carlo dose calculation, the fully integrated workflow faithfully replicates clinical techniques such as IMRT (intensity-modulated radiotherapy) and VMAT (volumetric modulated arc therapy). This not only makes research outcomes more clinically relevant but also significantly shortens study cycles.
3. Ultimate Dose Control for Both Efficacy and Safety
During treatment delivery, the SHARP 1000 achieves dose uniformity of ≥98%, supported by 3D tissue-equivalent dose modeling with >99% accuracy. This ensures highly effective tumor ablation while maximally sparing surrounding healthy tissues. Such exceptional precision provides researchers with reliable, objective experimental data for exploring mechanisms of radiotherapy combined with immunotherapy.
As a domestic brand specializing in high-end biomedical imaging and precision radiotherapy, Raycision has consistently focused on independent research and development, breaking long-standing foreign technological monopolies. The successful application of the SHARP 1000 not only highlights its technical prowess but also marks that China’s self-developed small-animal precision radiotherapy systems have reached internationally leading levels.
Looking ahead, Raycision will continue to deepen its technological innovation, delivering more advanced equipment and comprehensive solutions to support global researchers in tackling medical challenges and contributing Chinese wisdom and strength to the advancement of precision medicine.
